Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Green Cross Corp. has continued a trend among Korean pharma companies by posting relatively sluggish second quarter results
You may also be interested in...
In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant
SEOUL - Korea's sixth-largest pharma JW Choongwae Pharmaceutical Corp. has signed a memorandum of understanding with Kazakhstan's JSC Chempharm to build a manufacturing plant in Kazakhstan on a turn-key basis
In Medical Tourism Drive, Korea's JW Choongwae Links Up With Kazakhstan's JSC Chempharm To Build Manufacturing Plant
SEOUL - Korea's sixth-largest pharma JW Choongwae Pharmaceutical Corp. has signed a memorandum of understanding with Kazakhstan's JSC Chempharm to build a manufacturing plant in Kazakhstan on a turn-key basis
Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex